Randomized crossover feasibility trial of helminthicTrichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder
- PMID:30230399
- DOI: 10.1080/15622975.2018.1523561
Randomized crossover feasibility trial of helminthicTrichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder
Abstract
Objectives: Inflammatory mechanisms are implicated in the aetiology of autism spectrum disorder (ASD), and use of the immunomodulatorTrichuris suis Ova (TSO) is a novel treatment approach. This pilot study determined the effect sizes for TSO versus placebo on repetitive behaviours, irritability and global functioning in adults with ASD.Methods: A 28-week double-blind, randomised two-period crossover study of TSO versus placebo in ten ASD adults, aged 17-35, was completed, with a 4-week washout between each 12-week period at Montefiore Medical Center, Albert Einstein College of Medicine. Subjects with ASD, history of seasonal, medication or food allergies, Y-BOCS ≥6 and IQ ≥70 received 2,500 TSO ova or matching placebo every 2 weeks of each 12-week period.Results: Large effect sizes for improvement in repetitive behaviours (d = 1.0), restricted interests (d = 0.82), rigidity (d = 0.79) and irritability (d = 0.78) were observed after 12 weeks of treatment. No changes were observed in the social-communication domain. Differences between treatment groups did not reach statistical significance. TSO had only minimal, non-serious side effects.Conclusions: This proof-of-concept study demonstrates the feasibility of TSO for the treatment of ASD, including a favourable safety profile, and moderate to large effect sizes for reducing repetitive behaviours and irritability.Clinicaltrials.gov:NCT01040221.
Keywords: Autism spectrum disorder; Trichuris suis ova; cytokines; pharmacotherapy; repetitive behaviors.
Similar articles
- Safety and tolerability of medicinal parasite ova (Trichuris suis) in healthy Japanese volunteers: A randomized, double-blind, placebo-controlled trial.Hoshina T, Sakurai T, Ichimura H, Ishiwata K, En S, Yamada T, Kwangyole L, Shimizu A, Hase K, Kanuka H.Hoshina T, et al.Parasitol Int. 2021 Dec;85:102441. doi: 10.1016/j.parint.2021.102441. Epub 2021 Aug 21.Parasitol Int. 2021.PMID:34425258Clinical Trial.
- Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB.Sandborn WJ, et al.Aliment Pharmacol Ther. 2013 Aug;38(3):255-63. doi: 10.1111/apt.12366. Epub 2013 Jun 3.Aliment Pharmacol Ther. 2013.PMID:23730956Clinical Trial.
- A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H, Hesselbarth N, Teich N, Wehkamp J, Klaus J, Ott C, Dilger K, Greinwald R, Mueller R; International TRUST-2 Study Group.Schölmerich J, et al.J Crohns Colitis. 2017 Apr 1;11(4):390-399. doi: 10.1093/ecco-jcc/jjw184.J Crohns Colitis. 2017.PMID:27707789Free PMC article.Clinical Trial.
- Possible use of Trichuris suis ova in autism spectrum disorders therapy.Siniscalco D, Antonucci N.Siniscalco D, et al.Med Hypotheses. 2013 Jul;81(1):1-4. doi: 10.1016/j.mehy.2013.03.024. Epub 2013 Apr 15.Med Hypotheses. 2013.PMID:23597946Review.
- Trichuris suis ova therapy in inflammatory bowel disease: A meta-analysis.Huang X, Zeng LR, Chen FS, Zhu JP, Zhu MH.Huang X, et al.Medicine (Baltimore). 2018 Aug;97(34):e12087. doi: 10.1097/MD.0000000000012087.Medicine (Baltimore). 2018.PMID:30142867Free PMC article.Review.
Cited by
- Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?Suprunowicz M, Tomaszek N, Urbaniak A, Zackiewicz K, Modzelewski S, Waszkiewicz N.Suprunowicz M, et al.Nutrients. 2024 Feb 16;16(4):549. doi: 10.3390/nu16040549.Nutrients. 2024.PMID:38398873Free PMC article.Review.
- COVID-19 morbidity in lower versus higher income populations underscores the need to restore lost biodiversity of eukaryotic symbionts.Parker W, Patel E, Jirků-Pomajbíková K, Laman JD.Parker W, et al.iScience. 2023 Mar 17;26(3):106167. doi: 10.1016/j.isci.2023.106167. Epub 2023 Feb 9.iScience. 2023.PMID:36785786Free PMC article.Review.
- Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D.Iffland M, et al.Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.Cochrane Database Syst Rev. 2023.PMID:37811711Free PMC article.Review.
- Immune System Investigation Using Parasitic Helminths.Douglas B, Oyesola O, Cooper MM, Posey A, Tait Wojno E, Giacomin PR, Herbert DR.Douglas B, et al.Annu Rev Immunol. 2021 Apr 26;39:639-665. doi: 10.1146/annurev-immunol-093019-122827. Epub 2021 Mar 1.Annu Rev Immunol. 2021.PMID:33646858Free PMC article.Review.
- Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.Abdoli A, Mirzaian Ardakani H.Abdoli A, et al.Metab Brain Dis. 2020 Jan;35(1):95-110. doi: 10.1007/s11011-019-00466-5. Epub 2019 Jul 27.Metab Brain Dis. 2020.PMID:31352539Review.
Publication types
MeSH terms
Associated data
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical